Trial
NCT06844669
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
—
Condition
HER2-positive Breast Cancer
Intervention
Carvedilol
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-13